Genus Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Genus ha aumentado sus beneficios a una tasa media anual de 15.3%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento de 17.7% anual. Los ingresos han ido creciendo a una tasa media de 7.4% al año. La rentabilidad financiera de Genus es de 5.3%, y sus márgenes netos son de 5%.

Información clave

15.3%

Tasa de crecimiento de los beneficios

15.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	11.5%
Tasa de crecimiento de los ingresos	7.4%
Rentabilidad financiera	5.3%
Margen neto	5.0%
Próxima actualización de resultados	05 Sep 2024

Actualizaciones de resultados anteriores recientes

Recent updates

It's Unlikely That Shareholders Will Increase Genus plc's (LON:GNS) Compensation By Much This Year

Nov 17

Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217

Oct 25

Genus (LON:GNS) Is Paying Out A Dividend Of £0.217

Oct 11

Genus' (LON:GNS) Dividend Will Be £0.217

Sep 11

A Look At The Fair Value Of Genus plc (LON:GNS)

Sep 09

A Look At The Intrinsic Value Of Genus plc (LON:GNS)

May 31

Is Genus (LON:GNS) A Risky Investment?

Mar 29

Genus (LON:GNS) Has Re-Affirmed Its Dividend Of UK£0.10

Feb 27

Is Genus plc (LON:GNS) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 22

With EPS Growth And More, Genus (LON:GNS) Is Interesting

Oct 29

Here's Why Genus (LON:GNS) Can Manage Its Debt Responsibly

Oct 14

Genus (LON:GNS) Could Easily Take On More Debt

Apr 05

Is Genus' (LON:GNS) 235% Share Price Increase Well Justified?

Mar 18

Trade Alert: The Independent Non-Executive Chairman Of Genus plc (LON:GNS), Iain G. Ferguson, Has Just Spent UK£73k Buying 150% More Shares

Feb 28

I Ran A Stock Scan For Earnings Growth And Genus (LON:GNS) Passed With Ease

Feb 26

How Much Of Genus plc (LON:GNS) Do Institutions Own?

Feb 01

Genus plc (LON:GNS) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Dec 22

Have Genus plc (LON:GNS) Insiders Been Selling Their Stock?

Dec 05

Is Genus' (LON:GNS) Share Price Gain Of 195% Well Earned?

Nov 20

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Genus. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

LSE:GNS Ingresos, gastos y beneficios (GBP Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	673	33	101	93
30 Sep 23	681	33	100	93
30 Jun 23	690	33	99	93
31 Mar 23	676	34	94	83
31 Dec 22	662	34	90	73
30 Sep 22	628	38	89	73
30 Jun 22	593	41	89	73
31 Mar 22	582	39	92	71
31 Dec 21	570	37	95	68
30 Sep 21	572	42	96	68
30 Jun 21	574	47	97	68
31 Mar 21	570	45	93	70
31 Dec 20	566	42	89	71
30 Sep 20	559	39	89	71
30 Jun 20	551	35	88	71
31 Mar 20	536	37	80	66
31 Dec 19	520	39	72	61
30 Sep 19	504	23	72	61
30 Jun 19	489	8	72	61
31 Mar 19	480	1	76	56
31 Dec 18	471	-7	81	51
30 Sep 18	470	18	81	51
30 Jun 18	470	43	82	51
31 Mar 18	473	55	80	48
31 Dec 17	476	67	79	45
30 Sep 17	467	50	79	45
30 Jun 17	459	33	78	45
31 Mar 17	441	40	75	40
31 Dec 16	422	47	71	34
30 Sep 16	405	48	71	34
30 Jun 16	388	49	71	34
31 Mar 16	388	40	68	32
31 Dec 15	388	31	64	29
30 Sep 15	393	35	64	29
30 Jun 15	399	40	64	29
31 Mar 15	394	36	60	28
31 Dec 14	389	32	56	28
30 Sep 14	381	30	57	28
30 Jun 14	372	29	58	28
31 Mar 14	366	27	59	28
31 Dec 13	360	25	60	28
30 Sep 13	353	24	60	28
30 Jun 13	345	23	60	28

Ingresos de calidad: GNS tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(5%) de GNS son inferiores a los del año pasado (5.2%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: GNS ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de 15.3% al año.

Acelerando crecimiento: GNS ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: GNS tuvo un crecimiento negativo de los beneficios (-2.9%) durante el año pasado, lo que dificulta la comparación con la media de la industria Biotechs (-8.7%).

Genus Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Información clave

Actualizaciones de resultados anteriores recientes

First half 2024 earnings released: EPS: UK£0.21 (vs UK£0.20 in 1H 2023)

Genus plc to Report Fiscal Year 2024 Results on Sep 05, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Full year 2023 earnings: EPS exceeds analyst expectations

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.30 in 1H 2022)

Genus plc to Report Fiscal Year 2023 Results on Sep 07, 2023

Recent updates

Price target decreased by 7.9% to UK£28.74

Estimating The Fair Value Of Genus plc (LON:GNS)

Is Genus (LON:GNS) Using Too Much Debt?

With A 26% Price Drop For Genus plc (LON:GNS) You'll Still Get What You Pay For

Investor sentiment deteriorates as stock falls 15%

Price target decreased by 10% to UK£29.62

Genus (LON:GNS) Has Affirmed Its Dividend Of £0.103

First half dividend of UK£0.10 announced

First half 2024 earnings released: EPS: UK£0.21 (vs UK£0.20 in 1H 2023)

Consensus EPS estimates fall by 23%

Investor sentiment deteriorates as stock falls 19%

Genus plc Provides Earnings Guidance for the First Half of Fiscal 2024

Genus plc Provides Earnings Guidance for the First Half of Fiscal 2024

Getting In Cheap On Genus plc (LON:GNS) Might Be Difficult

Genus Appoints Ralph Heuser as Non-Executive Director, with effect from 1 January 2024

Does This Valuation Of Genus plc (LON:GNS) Imply Investors Are Overpaying?

Genus plc to Report Fiscal Year 2024 Results on Sep 05, 2024

Genus plc Approves to Declare Final Dividend

We Think Genus (LON:GNS) Is Taking Some Risk With Its Debt

Upcoming dividend of UK£0.22 per share at 1.4% yield

Full year 2023 earnings: EPS exceeds analyst expectations

Colombian Government Gives Positive Determination for Genus's PRRS Virus-Resistant Pigs

Colombian Government Gives Positive Determination for Genus's PRRS Virus-Resistant Pigs

Executive Director exercised options and sold UK£194k worth of stock

Consensus EPS estimates fall by 19%

Calculating The Intrinsic Value Of Genus plc (LON:GNS)

Full year 2023 earnings: EPS exceeds analyst expectations

Genus plc Announces Lykele Van Der Broek to Step Down from the Genus Board

AB Agri Ltd. completed the acquisition of National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd.

Price target decreased by 8.4% to UK£38.82

Now 20% undervalued after recent price drop

Price target decreased by 8.0% to UK£40.28

Is Genus (LON:GNS) A Risky Investment?

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.30 in 1H 2022)

Is Genus (LON:GNS) Using Too Much Debt?

Price target decreased to UK£40.14

Genus plc to Report Fiscal Year 2023 Results on Sep 07, 2023

It's Unlikely That Shareholders Will Increase Genus plc's (LON:GNS) Compensation By Much This Year

Investor sentiment improved over the past week

Upcoming dividend of UK£0.22 per share

Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217

Genus (LON:GNS) Is Paying Out A Dividend Of £0.217

Genus' (LON:GNS) Dividend Will Be £0.217

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

A Look At The Fair Value Of Genus plc (LON:GNS)

Investor sentiment improved over the past week

Genus plc Proposes Final Dividend, Payable on 9 December 2022

Investor sentiment improved over the past week

A Look At The Intrinsic Value Of Genus plc (LON:GNS)

Price target decreased to UK£46.05

Is Genus (LON:GNS) A Risky Investment?

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Genus (LON:GNS) Has Re-Affirmed Its Dividend Of UK£0.10

Genus plc Proposes Interim Dividend, Payable on March 31, 2022

Genus plc to Report First Half, 2022 Results on Feb 24, 2022

Is Genus plc (LON:GNS) Expensive For A Reason? A Look At Its Intrinsic Value

Independent Non-Executive Chairman recently bought UK£224k worth of stock

Upcoming dividend of UK£0.22 per share

With EPS Growth And More, Genus (LON:GNS) Is Interesting

Full year 2021 earnings released: EPS UK£0.73 (vs UK£0.54 in FY 2020)

Chief Operating Officer recently sold UK£336k worth of stock

Here's Why Genus (LON:GNS) Can Manage Its Debt Responsibly

Insider recently sold UK£1.4m worth of stock

Full year 2021 earnings released: EPS UK£0.73 (vs UK£0.62 in FY 2020)

Genus plc (LSE:GNS) acquired Trade and assets of Sergal Gestio Ramadera, S.L. from Sergal Gestio Ramadera Sl for £7.7 million.

Independent Non-Executive Director Ian Charles has left the company

Genus (LON:GNS) Could Easily Take On More Debt

Independent Non-Executive Chairman recently bought UK£72k worth of stock

Is Genus' (LON:GNS) 235% Share Price Increase Well Justified?

Desglose de ingresos y gastos
Beta